In Silico Approach and Immunohistochemical Evaluation of Azadirachta indica Bioactive Compound as Hsp90 Inhibitor and AIF Inductor in Hepatocellular Carcinoma

Hepatocellular carcinoma is primary malignant liver cancer, leading to the third of cancer death cases. Cancer has insensitivity to growth-inhibitory mechanisms and evasion of programmed cell death. Large numbers of Hsp70 and low expression of AIF play crucial roles in establishing cancer cell hallmarks. Here, we evaluate the effect apoptosis of bioactive compound of Azadirachta indica by in silico and in vivo approach. The protein was docked to the compounds using AutoDock Vina, visualized using Discovery Studio 4.1. In vivo experiment of the protein expression in liver organ from rat model hepatocellular carcinoma treated ethanolic extract of Azadircahta indica leaves was done by immunohistochemistry staining. Furthermore, the present molecular docking studies of bioactive compounds of Azadirachta indica may inhibit cancer development by binding to the active site of Hsp90 comparable to native ligand. An in vivo study on rat model of hepatocellular carcinoma by immunohistochemical stainning label with FIsp70 and AIF antibody showed brownish color aggregates on the su. The result of the treatment group was decreasing of Hsp70 and increasing AIF expression. The data obtained in this study demonstrate that ethanolic extract of Azadircahta indica leaves exerts a potent anticancer effect against hepatocellular carcinoma by altering key signaling pathways.